MTOR and Alzheimer disease: Increasing research indicates that the inhibition of TFEB kinases [64–66], activation of TFEB acetylation [21], and mTOR-dependent or -independent pharmacological activation of TFEB [52, 67, 68] have therapeutic potential in AD animal models.